High quality structure of cleaved PAI-1-stab

Journal of Structural Biology

Volumn 165, Issue 2, 2009, Pages 126-132

  Dewilde, M ^a   Strelkov, S V ^b   Rabijns, A ^b   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Crystal structure; PAI 1; Plasminogen activator inhibitor 1; Rational drug design; Serpin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN STABILITY; TEMPERATURE;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SERPINS;

EID: 58349083298     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2008.11.001     Document Type: Article

References (56)

1. Aertgeerts K., De Bondt H.L., De Ranter C.J., and Declerck P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 2 (1995) 891-897
2. Andreasen P.A., Egelund R., Jensen S., and Rodenburg K.W. Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb. Haemost. 81 (1999) 407-414
3. Audenaert A.M., Knockaert I., Collen D., and Declerck P.J. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J. Biol. Chem. 269 (1994) 19559-19564
4. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., and Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4 (1998) 923-928
5. Baumann U., Huber R., Bode W., Grosse D., Lesjak M., and Laurell C.B. Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins. J. Mol. Biol. 218 (1991) 595-606
6. Berkenpas M.B., Lawrence D.A., and Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14 (1995) 2969-2977
7. Bijnens A.P., Gils A., Knockaert I., Stassen J.M., and Declerck P.J. Importance of the hinge region between a-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275 (2000) 6375-6380
8. Bijnens A.P., Ngo T.H., Gils A., Dewaele J., Knockaert I., Stassen J.M., and Declerck P.J. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1. Thromb. Haemost. 85 (2001) 866-874
9. Brünger A.T. Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Crystallogr. D Biol. Crystallogr. 49 (1993) 24-36
10. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., Mulligan R.C., and Collen D. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J. Clin. Invest. 92 (1993) 2756-2760
11. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall III W.B., Snoeyink J., Richardson J.S., and Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-W383
12. De Taeye B., Gils A., and Declerck P.J. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant ?. Thromb. Haemost. 92 (2004) 898-924
13. Debrock S., and Declerck P.J. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim. Biophys. Acta 1337 (1997) 257-266
14. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Paques E.P., Preissner K.T., Muller Berghaus G., and Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263 (1988) 15454-15461
15. Declerck P.J., De Mol M., Vaughan D.E., and Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J. Biol. Chem. 267 (1992) 11693-11696
16. Egelund R., Rodenburg K.W., Andreasen P.A., Rasmussen M.S., Guldberg R.E., and Petersen T.E. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 37 (1998) 6375-6379
17. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
18. Erickson L.A., Fici G.J., Lund J.E., Boyle T.P., Polites H.G., and Marotti K.R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346 (1990) 74-76
19. Gils A., and Declerck P.J. Structure-function relationship in serpins: current concepts and controversies. Thromb. Haemost. 80 (1998) 531-541
20. Gils A., Knockaert I., and Declerck P.J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 35 (1996) 7474-7481
21. Hekman C.M., and Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260 (1985) 11581-11587
22. Huntington J.A., Read R.J., and Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 (2000) 923-926
23. Jensen J.K., and Gettins P.G.W. High resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci. 17 (2008) 184-1849
24. Juhan-Vague I., Alessi M.C., and Declerck P.J. Pathophysiology of fibrinolysis. Bail. Clin. Haematol. 8 (1995) 329-343
25. Kjoller L., Martensen P.M., Sottrup Jensen L., Justesen J., Rodenburg K.W., and Andreasen P.A. Conformational changes of the reactive-centre loop and beta- strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Eur. J. Biochem. 241 (1996) 38-46
26. Kruithof E.K., Tran Thang C., Ransijn A., and Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 64 (1984) 907-913
27. Kyte J., and Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1982) 105-132
28. Lawrence D., Strandberg L., Grundstrom T., and Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur. J. Biochem. 186 (1989) 523-533
29. Lawrence D.A., Olson S.T., Palaniappan S., and Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J. Biol. Chem. 269 (1994) 27657-27662
30. Loebermann H., Tokuoka R., Deisenhofer J., and Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177 (1984) 531-557
31. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 33 (1968) 491-497
32. McGowan S., Buckle A.M., Irving J.A., Ong P.C., Bashtannyk-Puhalovich T.A., Kan W.T., Henderson K.N., Bulynko Y.A., Popova E.Y., Smith A.I., Bottomley S.P., Rossjohn J., Grigoryev S.A., Pike R.N., and Whisstock J.C. X-ray crystal structure of MENT: evidence for functional loop-sheet polymers in chromatin condensation. EMBO J. 25 (2006) 3144-3155
33. Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., Gerard R.D., and Goldsmith E.J. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355 (1992) 270-273
34. Munch M., Heegaard C.W., and Andreasen P.A. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta 1202 (1993) 29-37
35. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
36. Nar H., Bauer M., Stassen J.M., Lang D., Gils A., and Declerck P.J. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297 (2000) 683-695
37. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology (1997), Academic Press, New York 307-326
38. Prins M.H., and Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch. Intern. Med. 151 (1991) 1721-1731
39. Ramachandran G.N., Ramakrishnan C., and Sasisekharan V. Stereochemistry of polypeptide chain configurations. J. Mol. Biol 7 (1963) 95-99
40. Sancho E., Tonge D.W., Hockney R.C., and Booth N.A. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur. J. Biochem. 224 (1994) 125-134
41. Schousboe S.L., Egelund R., Kirkegaard T., Preissner K.T., Rodenburg K.W., and Andreasen P.A. Vitronectin and substitution of a b-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against a-helix F. Thromb. Haemost. 83 (2000) 742-751
42. Sharp A.M., Stein P.E., Pannu N.S., Carrell R.W., Berkenpas M.B., Ginsburg D., Lawrence D.A., and Read R.J. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7 (1999) 111-118
43. Shore J.D., Day D.E., Francis Chmura A.M., Verhamme I., Kvassman J., Lawrence D.A., and Ginsburg D. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270 (1995) 5395-5398
44. Simonovic M., Gettins P.G.W., and Volz K. Crystal structure of viral serpin crmA provides insights into its mechanism of cysteine proteinase inhibition. Protein Sci. 9 (2000) 1423-1427
45. Stein, P.E., Baek, K., 2002. 1.8 Å resolution structure of latent plasminogen activator inhibitor-1. Protein data bank code 11j5.
46. Stoop A.A., Eldering E., Dafforn T.R., Read R.J., and Pannekoek H. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J. Mol. Biol. 305 (2001) 773-783
47. Stout T.J., Graham H., Buckley D.I., and Matthews D.J. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39 (2000) 8460-8469
48. Tucker H.M., Mottonen J., Goldsmith E.J., and Gerard R.D. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition [letter]. Nat. Struct. Biol. 2 (1995) 442-445
49. Urano T., Strandberg L., Johansson L.B., and Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur. J. Biochem. 209 (1992) 985-992
50. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
51. van Meijer M., and Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 9 (1995) 261-276
52. Vleugels N., Gils A., Mannaerts S., Knockaert I., and Declerck P.J. Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. Fibrinolysis Proteol. 12 (1998) 277-282
53. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand. J. Clin. Lab. Invest. 59 (1999) 23-31
54. Wind T., Jensen M.A., and Andreasen P.A. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 - Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur. J. Biochem. 268 (2001) 1095-1106
55. Xue Y., Björquist P., Inghardt T., Linschoten M., Musil D., Sjölin L., and Deinum J. Interfering with the inhibitory meachnism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6 (1998) 627-636
56. Zhou A., Huntington J.A., Pannu N.S., Carrell R.W., and Read R.J. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat. Struct. Biol. 10 (2003) 541-544